Heramed Ltd · ASX:HMD
Heramed — Investor Presentation (May 2021)
16 slides from Heramed's investor presentation, May 17, 2021
Slide 1: ASX Announcement: Updated Investor Presentation and Webinar
ASX ANNOUNCEMENT 17 May 2021 Updated Investor Presentation and Webinar For personal use only HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”), is pleased to provide an updated investor presentation (attached). On Wednesday 19 May, at 2:00 PM (Canberra, Melbourne, Sydney), HeraMED CEO and Cofou
Slide 2: Leading the digital transformation of maternity care
For personal use only HeraMED ASX:HMD May 2021 Leading the digital transformation of maternity care 1
Slide 3: HeraMED snapshot
HeraMED HeraMED offers a subscription-based, at-home hardware & software pregnancy care solution for snapshot For personal use only clinics, hospitals, insurers and digital platforms An FDA1, TGA and CE approved, Key IP: foetal heart rate monitor that can HeraBEAT be used at home, shown to be as acc
Slide 4: COVID-19 has fast-tracked telehealth globally
COVID-19 has Basic standard of care rarely met for pregnant mothers in rural and remote fast-tracked locations or in developing countries For personal use only telehealth globally However, basic standard of care for low- New solutions are needed to risk requires ~14 in-clinic visits, and much unlock
Slide 5: Solution overview
Solution HeraBEAT Maternity Care App HeraCARE Platform overview For personal use only At-home pregnancy care solution in B2B2C model, enabling clinics, hospitals, insurers • Foetal & maternal heart Complete pregnancy care • Enables personalised, and digital platforms rate monitoring device, app trac
Slide 6: HeraCARE - Becoming the digital hub for maternity care
Aggregates, analyses and highlights medical data from the HeraCARE - HeraBEAT and other smart devices allowing healthcare providers to be better informed, optimize their workflow, Becoming the For personal use only and become much more effective patient advocates digital hub for maternity care HeraC
Slide 7: Corporate strategy: Path to market
Corporate Path to market strategy For personal use only 2. Paid pilot 4. ‘Land and 1. Clinical with health 3. Broad Expand’ credibility care adoption in target providers markets In progress Near future Clinical studies with Pilots underway in Successful pilots Growing pipeline of leading healthcare
Slide 8: Clinical credibility
JHC Clinical Trial, Australia Clinical October 2020 credibility For personal use only 81 Results featured in globally pregnant women recognised scientific journal ‘Obstetrics & Gynecology’ 100% Detection of foetal heart rate Clinical trial with without assistance Mayo Clinic, USA 96-100% Satisfactio
Slide 9: Paid pilots with health care providers leading to adoption
Paid pilots with Paid pilots with major, recognised health care providers creates ‘on-ramp’ to user access health care For personal use only and first revenues providers leading to adoption Multiple discussions with Healthcare providers Mednax Mayo Clinic 100 1,200 Collaboration agreement, clinical
Slide 10: Established partnerships with leading health care providers
Established Joondalup Health Mednax The Mayo Clinic Sheba Hospital Campus (JHC) partnerships For personal use only with leading health One of Western The largest clinical services provider in the Ranked #1 in the World’s Ranked #9 in the World’s care providers Australia’s largest hospitals and a lea
Slide 11: Land and Expand in key territories
Channel partner / Land and customer categories Expand in key For personal use only territories Hospitals and clinics HeraMED solution One-off hardware device sale ~US$200 Maternity Multiple health groups partnerships in pipeline with access to Monthly SaaS fee ~US$50 hundreds of per pregnant woman p
Slide 12: Key growth drivers
Key growth drivers For personal use only Only clinically 100% accuracy of CE, TGA and FDA1 validated, HeraBEAT device clearance for maternity care creates at-home HeraBEAT in platform maternity care market clinical or at-home settings COVID-19 presents Pilot programs with B2B2C model reduces opportu
Slide 13: Board & Management
Board & Dr. Ron Weinberger • Highly-experienced international business executive with strong scientific background • Former Director, President and CEO of Nanosonics Ltd. (ASX: NAN), Mkt cap ~$2 billion Management Non-Executive Chairman For personal use only • CEO and MD of EMVision Ltd. ASX:EMV, No
Slide 14: Share price, market cap and shareholders
A$0.155 A$27.4m US$2.7m Share Price Market Cap Cash (as at 30 March 2021) For personal use only Leading the digital transformation of Shareholder Shares (m) (%) 1 Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> 11.3m 6.4% maternity care 2 3 Altshuler Shaham Trusts Ltd <Holley Pharma Co Ltd A
Slide 15: Disclaimer
Disclaimer Important notice regarding forward looking statements For personal use only This document contains a general summary of the company and is provided for information purposes only. For full details please review HeraMED Limited ACN 626 295 314 (HeraMED) ASX page - https://www.asx.com.au/asx
Slide 16: Contact
For personal use only Contact HeraMED David Groberman, CEO and Co-Founder M: +972 52 699 1188 E: david@hera-med.com Jonathan Hart, Company Secretary M: +61 2 8379 2961 E: jonathan@hera-med.com PAC Partners Tim Chapman, Director M: +61 419 897 062 E: tchapman@pacpartners.com.au 15